Boundless Bio (BOLD) is a clinical-stage precision oncology company focused on ecDNA-directed therapeutics (ecDTx), remaining pre-revenue.
Financial Performance (9 Months Ended 9/30/2025): Net Loss narrowed year-over-year to \(\\)(45.3M)\( (from \)$(48.9M)\( in 2024). Diluted Loss Per Share improved significantly to \)$(2.03)\( (from \)$(3.22)\(), amplified by a larger weighted-average share count (22.3M shares used in 2025 calculation). Total operating expenses decreased to \)$49.55M\(, driven by a substantial reduction in R&D outsourced consulting costs (\\)8.29M vs. $14.98M in 2024). However,
...